RNA Analytical/Quality Videos

  1. Advancing Peptide Characterization Of Critical Quality Attributes With MMS 11/12/2025

    Axxium uncovered hidden peptide aggregation using MMS technology, revealing process-related potency issues missed by conventional methods. Learn how advanced structural analysis can strengthen quality control and biologics development.

  2. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.

  3. Beyond Cas9: How Diverse Nucleases are Redefining gRNA Design 4/29/2026

    As CRISPR technology evolves beyond the original Cas9, gRNAs are transitioning from simple targeting tools into highly engineered, complex molecules. In this Advancing RNA Live segment, speakers April Sena, Max De Long, and Venkat Krishnamurthy discuss how the rise of diverse nucleases — including prime editors — is impacting gRNA synthesis and purity.

  4. What The EMA Guidance Means For mRNA: Progress, Limitations, And Future Directions 6/24/2025

    Advancing RNA panelists Tiffany Lucas and Ulrike Jägle home in on the EMA’s guidance for mRNA vaccine quality, sharing their initial thoughts on the guidance’s strengths, while also addressing its limitations for those of us who may be working with mRNA in a therapeutic context.

  5. The Current State of CDMO Platforms For gRNA Production 4/29/2026

    Max De Long, April Sena, and Venkat Krishnamurthy share their perspectives on the current “health” of CDMO SPOS and enzymatic ligation platforms, while also highlighting the “red flags” to look out for when taking stock of a CDMOs capabilities. 

  6. Beyond Purity: Addressing the FDA's CMC Expectations for gRNA 4/29/2026

    Advancing RNA Live panelists Venkat Krishnamurthy, April Sena, and Max De Long share their perspectives on the most important regulatory considerations for gRNA production utilizing an enzymatic ligation approach.

  7. What's In The Vial?! A [Brief] Meditation On Control Strategy

    Speakers in The State Of The mRNA Supply Chain event tackle an audience member’s question around what matters most: What’s in the vial or what’s in the process?

  8. The Evolutions Of mRNA Analytical Development (So Far) 8/22/2024

    Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.

  9. Establishing Analytical Methods For Emerging mRNA-Based Therapies 6/5/2023

    Here, we describe the use of cutting-edge technologies to assess critical quality attributes of both mRNA drug substances and drug products.

  10. Closing the Gap: How NIST is Addressing gRNA Quality 4/29/2026

    Life Edit Therapeutics’ April Sena provides an update on NIST’s gene editing consortium, teasing forthcoming deliverables from a working group focused on gRNA quality.